Liu Lijuan, Ma Xiao, Liu Juan, Fu Jinhua, Li Ning, Yuan Guiling, Zhao Long
Department of Obstetrics, Qingdao Jinhua Gynecology Hospital, Qingdao, Shandong, China.
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
BMC Pregnancy Childbirth. 2025 Apr 21;25(1):463. doi: 10.1186/s12884-025-07600-5.
In order to examine the impact of belimumab on recurrent spontaneous abortion (RSA) women exhibiting B lymphocyte dysfunction.
This study conducted a retrospective case-control analysis of RSA patients with confirmed B lymphocyte dysfunction. The study included 102 women who had experienced at least two consecutive miscarriages and demonstrated elevated peripheral blood B cell percentages and/or counts. Participants were separated into two distinct groups: the belimumab group (n = 51), which received basic treatment supplemented with belimumab (BENLYSTA) at a dosage of 10 mg/kg BW at 2-week intervals for the first 3 doses and at 4-week intervals thereafter, from the end of menstrual period until the 12th week of pregnancy, if necessary; and the control group (n = 51), which received only standard treatment. Comparisons of Pregnancy outcomes, B cell percentage, B cell count and adverse reactions were made between 2 groups.
Healthy newborns were delivered by 45 participants (88.23%) in belimumab group and 36 participants (70.59%) in control group [P = 0.048, odds ratio (OR) = 3.13; 95% confidence interval (CI) (1.10-8.87)]. The belimumab group exhibited significantly lower peripheral blood B cell percentage and B cell count compared to the control group during gestational weeks 2-12 (P < 0.05).
The findings suggest that belimumab is both safe and effective for treating RSA with lymphocyte dysfunction, indicating its potential as a therapeutic strategy for RSA.
探讨贝利尤单抗对表现出B淋巴细胞功能障碍的复发性自然流产（RSA）女性的影响。
本研究对确诊为B淋巴细胞功能障碍的RSA患者进行回顾性病例对照分析。研究纳入了102名经历过至少两次连续流产且外周血B细胞百分比和/或计数升高的女性。参与者被分为两个不同的组：贝利尤单抗组（n = 51），在必要时，从月经周期结束至妊娠第12周，接受基础治疗并补充贝利尤单抗（倍力腾），前3剂每2周一次，剂量为10 mg/kg体重，此后每4周一次；对照组（n = 51），仅接受标准治疗。比较两组的妊娠结局、B细胞百分比、B细胞计数和不良反应。
贝利尤单抗组45名参与者（88.23%）和对照组36名参与者（70.59%）分娩出健康新生儿[P = 0.048，优势比（OR）= 3.13；95%置信区间（CI）（1.10 - 8.87）]。在妊娠第2 - 12周期间，贝利尤单抗组外周血B细胞百分比和B细胞计数显著低于对照组（P < 0.05）。
研究结果表明，贝利尤单抗治疗淋巴细胞功能障碍的RSA既安全又有效，表明其作为RSA治疗策略的潜力。
